Cited by 336Neuroinflammation and Neurodegeneration MechanismsMultiple Sclerosis Research StudiesAlzheimer's disease research and treatments

Immune Signaling in Neurodegeneration

Open access
Hammond, Timothy R., Marsh, Samuel E., Stevens, Beth·2019·Immunity

Abstract

Neurodegenerative diseases of the central nervous system progressively rob patients of their memory, motor function, and ability to perform daily tasks. Advances in genetics and animal models are beginning to unearth an unexpected role of the immune system in disease onset and pathogenesis; however, the role of cytokines, growth factors, and other immune signaling pathways in disease pathogenesis is still being examined. Here we review recent genetic risk and genome-wide association studies and emerging mechanisms for three key immune pathways implicated in disease, the growth factor TGF-β, the complement cascade, and the extracellular receptor TREM2. These immune signaling pathways are important under both healthy and neurodegenerative conditions, and recent work has highlighted new functional aspects of their signaling. Finally, we assess future directions for immune-related research in neurodegeneration and potential avenues for immune-related therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2019.03.016

Cites

268 of 268 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AD pathology is characterized by extracellular amyloid plaques and intracellular NFTs surrounded by immune cells, especially microglia; clinical manifestation is progressive cognitive impairment.

    “The pathology of AD is characterized by extracellular amyloid plaques and intracellular NFTs, which are surrounded by immune cells, especially microglia; the clinical manifestation of AD is characterized by progressive cognitive impairment.14”

    From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [14]

    The “Clinical & Pathological Characteristics of Neurodegenerative Disease” section describes extracellular amyloid-beta plaques, intracellular tau tangles, and progressive cognitive decline in AD. It places immune cells, likely microglia, close to plaques, but does not say they surround the tangles. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • The shared associations in chr6 region with both immunological and neurodegenerative traits adds evidence to the known relationship between these two processes.

    “The shared associations in this region with both immunological and neurodegenerative traits adds evidence to the known relationship between these two processes36.”
  • Aβ binds to microglial TREM2, activating TREM2 signaling and leading to enhanced phagocytosis.

    “Aβ binds to microglial TREM2, which activates TREM2 signaling and lead to the enhanced phagocytosis of microglia.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 6

  1. Denk F, and Wade-Martins R (2009). Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging 30, 1– 13. 17590238 PMC2806682
  2. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay M, Hofstetter R, and Klauber M (1990). The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 40, 1– 8. 2153271
  3. Mancuso R, Van Den Daele J, Fattorelli N, Wolfs L, Balusu S, Burton O, Sierksma A, Fourne Y, Poovathingal S, Arranz-Mendiguren A, (2019). Stem cell derived human microglia transplanted in mouse brain to study genetic risk of Alzheimer's Disease. bioRxiv, 562561. PMC7616913 31659342
  4. McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard C, (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88– 100. 28592453 PMC5496518
  5. McVicar DW, Taylor LS, Gosselin P, Willette-Brown J, Mikhael AI, Geahlen RL, Nakamura MC, Linnemeyer P, Seaman WE, Anderson SK, (1998). DAP12-mediated Signal Transduction in Natural Killer Cells: A DOMINANT ROLE FOR THE Syk PROTEIN-TYROSINE KINASE. Journal of Biological Chemistry 273, 32934– 32942. 9830044
  6. Tanzi R (2012). The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2. PMC3475404 23028126

Cited by

Sorted by citations

Authors
Hammond, T. R., Marsh, S. E., & Stevens, B.
Affiliations
Broad Institute (US)
Corresponding author
Stevens, Beth
Venue
Immunity
Publisher
Elsevier BV
Published
2019-04
Volume
50
Issue
4
Pages
955-974
ISSN
1074-7613 (ISSN-L)
OpenAlex
W2938743978
Cited by
336
References
268
Citations by year
2026: 32 · 2025: 42 · 2024: 46 · 2023: 58 · 2022: 52 · 2021: 46 · 2020: 47 · 2019: 12 · 2018: 1
FWCI
4.06
Type
journal article
Language
en
Open access
Locations
  • Immunity (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD090255, 2018, 2019)
  • Cure Alzheimer's Fund
  • National Institute on Aging (1RF1AG051496)
  • National Institute of Neurological Disorders and Stroke (WO2015103594A1/US20160327572A1, US8148330B2, US9149444B2)
  • National Institutes of Health
  • National Cancer Institute
  • National Institute on Drug Abuse
  • National Heart, Lung, and Blood Institute
  • National Institute of Mental Health
  • National Human Genome Research Institute
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
neurodegeneration, immune signaling, TGF-beta, complement system, TREM2, cytokines, growth factors, genetic risk factors, genome-wide association study, neuroinflammation
MeSH terms
Aging, Animals, Complement Activation, Gliosis, Humans, Immunity, Innate, Inflammation, Membrane Glycoproteins, Mice, Transgenic, Receptors, Immunologic, Signal Transduction, Transforming Growth Factor beta, Microglia, Mice, Knockout, Models, Immunological, Disease Progression, Neurodegenerative Diseases, Genetic Predisposition to Disease, Mice, Genome-Wide Association Study, Protein Aggregation, Pathological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review